Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
24.18
-1.59 (-6.17%)
At close: Feb 4, 2026, 4:00 PM EST
24.18
0.00 (0.00%)
After-hours: Feb 4, 2026, 6:03 PM EST
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$137
Profits / Employee
-$1,085,533
Market Cap
509.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% | 300 | 0 |
| Dec 31, 2023 | 224 | -50 | -18.25% | 224 | 0 |
| Dec 31, 2022 | 274 | 55 | 25.11% | 274 | 0 |
| Dec 31, 2021 | 219 | 29 | 15.26% | 219 | 0 |
| Mar 31, 2021 | 190 | - | - | 188 | 2 |
| Dec 31, 2020 | 190 | - | - | 188 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| 4D Molecular Therapeutics | 227 |
| Vor Biopharma | 154 |
| Gossamer Bio | 145 |
| Solid Biosciences | 100 |
| Invivyd | 100 |
| Zevra Therapeutics | 59 |
| Contineum Therapeutics | 41 |
LYEL News
- 6 weeks ago - Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data - Seeking Alpha
- 2 months ago - Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer - GlobeNewsWire
- 3 months ago - Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 6 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewsWire